Fifth Third Bancorp Purchases 33,785 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Fifth Third Bancorp lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 9,598.0% during the first quarter, Holdings Channel reports. The institutional investor owned 34,137 shares of the specialty pharmaceutical company’s stock after buying an additional 33,785 shares during the quarter. Fifth Third Bancorp’s holdings in Supernus Pharmaceuticals were worth $1,765,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Rockefeller Capital Management L.P. grew its holdings in Supernus Pharmaceuticals by 354.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 660 shares during the last quarter. Torren Management LLC acquired a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth $49,000. Hantz Financial Services Inc. raised its stake in Supernus Pharmaceuticals by 73.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 458 shares during the last quarter. Global Retirement Partners LLC grew its stake in shares of Supernus Pharmaceuticals by 532.4% during the fourth quarter. Global Retirement Partners LLC now owns 1,404 shares of the specialty pharmaceutical company’s stock worth $70,000 after acquiring an additional 1,182 shares during the last quarter. Finally, Vestcor Inc purchased a new stake in shares of Supernus Pharmaceuticals during the third quarter worth about $67,000.

Wall Street Analysts Forecast Growth

SUPN has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Wall Street Zen raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 4th. Finally, Cantor Fitzgerald lifted their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $62.83.

Supernus Pharmaceuticals Price Performance

SUPN stock opened at $46.94 on Thursday. The firm’s fifty day simple moving average is $46.63 and its 200-day simple moving average is $49.28. The company has a market capitalization of $2.72 billion, a P/E ratio of -92.04, a price-to-earnings-growth ratio of 1.02 and a beta of 0.54. Supernus Pharmaceuticals, Inc. has a 12 month low of $32.51 and a 12 month high of $59.68.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.